Major U.S. insurers appear to be opening up to a relatively new and expensive class of cholesterol-lowering drugs. They accepted nearly three-fourths of claims for the drugs in 2017, according to a new report — a marked improvement from prior years.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,